Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.70 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7033981 | 1.00 | MEN1 (0.70) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| Hydrochloric Acid SCHEMBL7027080 | 0.99 | MEN1 (0.68) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| Phosphoric Acid SCHEMBL7022139 | 0.96 | MEN1 (0.64) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| Sulfuric Acid SCHEMBL7598698 | 0.96 | MEN1 (0.64) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| Sulfuric Acid SCHEMBL7025416 | 0.96 | MEN1 (0.64) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| SCHEMBL7536453 | 0.91 | ADRB3 (0.62) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| SCHEMBL7536027 | 0.91 | ADRB3 (0.62) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| Citric Acid SCHEMBL7027623 | 0.91 | MEN1 (0.57) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| SCHEMBL7613177 | 0.90 | MEN1 (0.65) | MEN1OPRM1OPRD1KMT2AABCB1 | |
| SCHEMBL7612538 | 0.90 | MEN1 (0.71) | MEN1OPRM1OPRD1KMT2AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | claimed |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-25 | — | — | US | claimed |
| US-20030032834-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-13 | — | — | US | claimed |
| EP-1257528-A1 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | claimed |
| WO-2001060786-A1 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | claimed |
| EP-1107944-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012462-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-09 | — | — | WO | claimed |
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| US-20030032834-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1257528-A1 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001060786-A1 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| EP-1107944-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012462-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | MEN1 3533/4885OPRM1 103/4885OPRD1 34/4885 |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | MEN1 3327/4885OPRM1 110/4885OPRD1 34/4885 |
| US-20030032834-A1 | Aminoalcohol derivatives | ADRB1, ADRB2, ADRB3 | MEN1 4166/4885OPRM1 35/4885OPRD1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.